FREIXENET COPESTICK LIMITED
Company number 05465686 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Financial Health Assessment: FREIXENET COPESTICK LIMITED
1. Financial Health Score: B-
Explanation: The patient is fundamentally healthy—growing revenue, positive net assets, and strong parent company backing—but is exhibiting acute symptoms of cash flow distress and margin compression that require immediate attention. The dramatic 89% decline in cash reserves is akin to a sudden drop in blood pressure; while the body is functioning, it's operating under significant strain.
2. Key Vital Signs
| Vital Sign | 2023 | 2022 | Trend | Interpretation |
|---|---|---|---|---|
| Net Turnover | £140.7m | £136.8m | +2.85% ↑ | Healthy pulse – revenue growing modestly |
| Gross Profit | £20.8m | £21.2m | -2.00% ↓ | Concerning – margin compression detected |
| Gross Margin | 14.78% | 15.50% | -0.72pp ↓ | Arterial narrowing – profitability under pressure |
| Net Assets | £30.07m | £29.00m | +3.69% ↑ | Positive – balance sheet strengthening |
| Total Liabilities | £69.08m | £67.93m | +1.69% ↑ | Debt levels rising, though proportionally controlled |
| Cash Position | £387k | £3.68m | -89.5% ↓ | Critical warning sign – severe cash depletion |
| Debt-to-Equity Ratio | 2.30:1 | 2.34:1 | Slight improvement | High leverage, though marginally better |
| Shareholders' Funds | £30.07m | £29.00m | +3.69% ↑ | Equity base growing – positive sign |
3. Diagnosis
Primary Condition: Cash Flow Hemorrhage
The most alarming symptom is the precipitous drop in cash from £3.68 million to just £387,000—a near 90% decline. In medical terms, this represents a severe case of cash flow anemia. While the patient has a healthy heartbeat (growing revenue) and reasonable organ function (positive net assets), the blood supply to sustain day-to-day operations has become dangerously thin.
This cash depletion likely stems from several compounding factors: - Working capital pressure: Inflation driving up inventory costs and supplier payment terms - Margin compression: Cost of goods rising faster than selling prices - Investment in brands: The strategic report indicates continued brand investment - Potential debtor stretching: Customers potentially taking longer to pay
Secondary Condition: Margin Sclerosis
Despite revenue growth of 2.85%, gross profit actually declined by £424,000. This is the financial equivalent of arterial hardening—the business is working harder (more revenue) but getting less nourishment (lower profit). The gross margin has narrowed from 15.50% to 14.78%, indicating that cost inflation is outpacing pricing power.
Positive Indicators
- Revenue resilience: Outperforming the broader sparkling wine market (-5.1% vs. market decline of -7.3%)
- Equity growth: Net assets increased by over £1 million
- Parent backing: Henkell International Gmbh owns >75% of shares, providing a potential financial safety net
- Filing compliance: Accounts and confirmation statements are up to date—no regulatory delinquency
Risk Factors
The strategic report identifies several environmental pathogens: - Inflation and mild recessionary conditions - Middle East conflict disrupting shipping routes and costs - Consumer downtrading to less premium products - Low/no-alcohol category both threatening and offering opportunity - Foreign exchange exposure across multiple currencies
4. Recommendations
Immediate Treatment (0-3 months)
1. Cash Flow Resuscitation - Conduct an urgent cash flow forecast to identify the root cause of the £3.3 million cash decline - Review working capital management: inventory levels, debtor days, and creditor payment terms - Consider whether intercompany funding from Henkell International can provide short-term liquidity support - Examine if the cash decline represents investment (potentially healthy) or operational drain (concerning)
2. Margin Preservation Therapy - Implement pricing reviews to recover cost inflation where market conditions allow - Analyze product mix to understand the impact of consumer downtrading on margin - Review supplier contracts and consolidate purchasing power through the Henkell group network
Medium-term Rehabilitation (3-12 months)
3. Debt Structure Review - With a debt-to-equity ratio of 2.30:1, the business is highly leveraged - Review the maturity profile of debt and ensure refinancing needs are addressed well in advance - Consider whether some short-term liabilities could be restructured to longer-term facilities
4. Category Strategy Adjustment - Accelerate participation in the growing Low & No category to capture shifting consumer demand - Protect premium brand positioning while developing accessible price-point offerings - Leverage the outperformance vs. market to strengthen retailer relationships
Long-term Wellness (12+ months)
5. Currency Risk Management - Formalize hedging strategies given multi-currency exposure - Consider natural hedging opportunities through the Henkell International group structure
6. Cash Conversion Improvement - Target a minimum cash reserve threshold (suggest 3-5% of revenue as a working buffer) - Implement cash conversion cycle monitoring and reporting
Prognosis
Cautiously Positive with Close Monitoring Required
The underlying business is fundamentally sound—revenue is growing, market share is being defended, and the parent company provides strategic and financial backing. However, the severe cash depletion and margin compression are symptoms that, if left untreated, could escalate into more serious liquidity constraints. The immediate priority is diagnosing exactly where the cash has gone and whether this represents a temporary investment phase or a structural working capital problem.
With appropriate intervention on cash management and margin recovery, this patient has strong prospects for returning to robust financial health. The mild recession and inflationary environment present headwinds, but the company's market outperformance suggests competitive resilience.